A Lisbon-based company is redefining natural medicine by focusing on plant-based, science-supported remedies. Biocol Labs, an offshoot of a family-run laboratory established in 1977, develops solutions targeting specific health issues rather than general wellness. The company seeks to provide alternatives to conventional pharmaceuticals, emphasizing clinical validation for its ingredients. With a direct-to-consumer approach, it aims to differentiate itself in a market dominated by traditional pharmacies.
Biocol Labs initially entered the market by offering natural over-the-counter (OTC) medicine, which positioned the company as an alternative to traditional drugstore products. Over time, it expanded its focus to specific health concerns such as liver detoxification, immunity support, and fatigue recovery. Although the company faced challenges related to economic fluctuations and digital advertising, it adapted by refining its product offerings and emphasizing scientific validation. This shift aligns with a broader industry movement toward evidence-based natural medicine.
What makes Biocol Labs’ approach different?
Rather than categorizing its products as general dietary supplements, Biocol Labs emphasizes their targeted medical benefits. The company avoids homeopathy and trends lacking scientific support, instead selecting ingredients with proven effects. According to Co-CEO Christian Balivet, Biocol Labs’ approach is centered on effectiveness rather than short-term relief.
“We aim to bridge the gap between supplements and prescription drugs by solving medical issues with natural solutions that are scientifically validated. We are not here to make you feel good, we are here to fix your problem.”
How does the company distribute its products?
Instead of relying on conventional pharmacies, Biocol Labs sells directly to consumers and through non-traditional retail channels such as design hotels, concept stores, and bars. The company’s pricing reflects the quality of its ingredients, which are naturally sourced rather than synthetically manufactured. While its products are considered costly in Europe, they have found a strong customer base in the U.S., where consumers are accustomed to investing in health products.
One of its most notable products is a liver detox solution, which gained popularity despite initial plans to discontinue it. This led the company to explore fatty liver disease, a condition often overlooked despite its link to various health issues. With no FDA-approved pharmaceutical treatments available, Biocol Labs sees natural medicine as a potential solution.
“The liver doesn’t distinguish between a tequila shot and a sugary frappuccino. In the U.S., up to 20 percent of teenagers already show signs of fatty liver disease.”
With €3.2 million raised in funding from investors such as Future Positive and industry leaders from Spotify, Glossier, and Prose, Biocol Labs is now working on expanding further. Its next steps include launching diagnostic tools to help consumers track liver health and continuing to refine its product formulations.
As demand for natural medicine grows, companies like Biocol Labs are shifting the conversation from wellness trends to evidence-based healthcare alternatives. The company’s approach reflects a broader industry movement toward solutions that do not solely rely on pharmaceuticals. However, challenges remain regarding consumer perception, regulatory classification, and scientific scrutiny. While natural medicine offers potential benefits, verifying the efficacy of such products remains critical for their long-term acceptance in mainstream healthcare.
